Den europeiske union -
norsk -
EMA (European Medicines Agency)
virbagen omega
virbac s.a. - rekombinant omega interferon av feline opprinnelse - immunostimulants, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. hos katter infisert av fiv var dødeligheten lav (5%) og ble ikke påvirket av behandlingen.
Norge -
norsk -
Statens legemiddelverk
moxonidin actavis 0.2 mg
actavis group ptc ehf (1) - moksonidin - tablett, filmdrasjert - 0.2 mg
Norge -
norsk -
Statens legemiddelverk
moxonidin actavis 0.4 mg
actavis group ptc ehf (1) - moksonidin - tablett, filmdrasjert - 0.4 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
alpivab
biocryst - peramivir - influensa, human - antivirale midler til systemisk bruk - alpivab er angitt for behandling av ukomplisert influensa i voksne og barn fra en alder av 2 år.